{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"what-are-peptides-neuropathy","title":"What Are Peptides for Neuropathy","body":"## What's breaking down\n\nNeuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.\n\nRepair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.\n\n## How these fit together\n\nDifferent peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.\n\n## What the evidence actually shows\n\nHuman data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)\n\nARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, patients reported lower neuropathic symptom scores and better quality of life after four weeks. Corneal confocal microscopy showed increased small nerve fiber density in one trial after 28 days. Skin biopsies did not show the same regrowth. Pain relief reached about 25-40 percent in some measures. (sources from Pain Reports 2016 and related PMC articles)\n\nPreclinical work on BPC-157 used rat models of sciatic nerve transection and spinal cord injury. Treated rats showed faster functional recovery, thicker regenerating axons, and better organized nerve bundles under microscope. These studies count as animal evidence only. Human reports remain limited to one small retrospective knee pain series with no neuropathy-specific outcomes.\n\nSemax studies in rats demonstrated reduced pain sensitivity and improved learning after intraperitoneal or intranasal dosing. Russian clinical use exists for stroke and encephalopathy, yet specific large neuropathy trials are absent from English-language records.\n\n## What scientists say\n\nResearchers describe ARA290 as reprogramming a damaging inflammatory environment into one that supports repair via the innate repair receptor. They note measurable symptom gains and early structural hints in cornea but call for larger trials. C-peptide investigators observed selective sensory improvement without broad electrophysiologic change and concluded further study is warranted. Animal researchers on BPC-157 highlight consistent nerve healing across trauma models yet stress the gap to human application.\n\n## What people say on Reddit\n\nUsers in neuropathy and small fiber neuropathy forums discuss ARA290 most often. Several report symptom relief within hours to days at doses around 4 mg daily for weeks. Some note reduced allodynia and burning. Others describe pins-and-needles flares that led them to stop. Cost and sourcing concerns appear repeatedly. A few mention combining with other approaches. BPC-157 threads focus more on general healing claims than documented neuropathy outcomes. Experiences remain anecdotal and vary widely.\n\n## What people say on X\n\nPublic posts on X about peptides for neuropathy stay sparse compared with Reddit. Occasional mentions link ARA290 to nerve repair discussions, often referencing the same human trials. Users rarely share personal outcome details in searchable posts. Broader peptide conversations emphasize research status over personal results.\n\n## What we do not know\n\nLarge phase III trials confirming long-term nerve regrowth or durable symptom control are missing for most compounds. Optimal dosing, duration, and patient selection remain unclear. Whether benefits continue after stopping treatment is unknown. Head-to-head comparisons between peptides do not exist. Effects on different neuropathy subtypes, such as chemotherapy-induced or idiopathic, lack dedicated data. Long-term safety beyond short trial periods is unproven.\n\n## Safety and limits\n\nReported side effects in human ARA290 and C-peptide trials stayed low with no major signals. Animal BPC-157 work shows no obvious toxicity at tested levels. Human experience overall remains small in scale. These compounds sit outside routine approved use for neuropathy in most regions. Any consideration requires medical oversight and awareness that evidence grades range from small human trials to animal models only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Long-acting C-peptide improved vibration perception threshold by 25% versus placebo in a 52-week RCT of 250 type 1 diabetes patients with neuropathy, but did not improve nerve conduction velocity or clinical scores.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human outcome data separates sensory improvement from other measures.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA290 increased corneal small nerve fiber density and reduced neuropathic symptom scores in placebo-controlled trials of patients with sarcoidosis-associated small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides both symptom and structural human evidence.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"BPC-157 promoted axon regeneration and functional recovery after sciatic nerve transection in rat models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Animal data on structural nerve repair; no equivalent human neuropathy trials.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report variable symptom relief with ARA290, including reduced burning and allodynia in some cases alongside occasional flares.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26884473/","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes","quote":"After 52 weeks, ... VPT had improved by 25% after 52 weeks of C-peptide therapy ... but resulted in marked improvement of VPT compared with placebo.","summary":"52-week RCT details on C-peptide effects in diabetic neuropathy.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"357b6ac77132eb3b8cb769b9e775eb7176179a3d49504ee8f2e0181da059c2ef"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"ARA290 treatment over 28 days increased corneal small nerve fiber density ... In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms.","summary":"Human trial summaries on ARA290 for small fiber neuropathy.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"357b6ac77132eb3b8cb769b9e775eb7176179a3d49504ee8f2e0181da059c2ef","hash":"faae3246c0170a573a2881385e7e6b2e71eefa5bb8451b52d271a5a0361a1898"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/","title":"Stable gastric pentadecapeptide BPC 157 can improve ...","quote":"BPC 157 ... therapeutic effects ... in spinal cord injury using a rat model. Spinal cord injury recovery was ...","summary":"Rat studies on BPC-157 nerve and spinal repair.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"faae3246c0170a573a2881385e7e6b2e71eefa5bb8451b52d271a5a0361a1898","hash":"d3fe610e699cbdb1daba348b8776fa33fd6c8f6fc58532104101e79a26836df4"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/","title":"Peptide ARA-290","quote":"Has anyone tried the peptide ARA-290. It has clinical evidence of helping to slow or stop neuropathy and allow nerves to heal.","summary":"Reddit discussion thread on ARA290 user experiences.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"d3fe610e699cbdb1daba348b8776fa33fd6c8f6fc58532104101e79a26836df4","hash":"9aeb19dfe2f2e8c91261c01ae6e00f99ccaff8daa83ae9e95cd260a2695d3055"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T21:52:50.194Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for Neuropathy","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.\n\nRepair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.\n\n## How these fit together\n\nDifferent peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.\n\n## What the evidence actually shows\n\nHuman data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)\n\nARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, patients reported lower neuropathic symptom scores and better quality of life after four weeks. Corneal confocal microscopy showed increased small nerve fiber density in one trial after 28 days. Skin biopsies did not show the same regrowth. Pain relief reached about 25-40 percent in some measures. (sources from Pain Reports 2016 and related PMC articles)\n\nPreclinical work on BPC-157 used rat models of sciatic nerve transection and spinal cord injury. Treated rats showed faster functional recovery, thicker regenerating axons, and better organized nerve bundles under microscope. These studies count as animal evidence only. Human reports remain limited to one small retrospective knee pain series with no neuropathy-specific outcomes.\n\nSemax studies in rats demonstrated reduced pain sensitivity and improved learning after intraperitoneal or intranasal dosing. Russian clinical use exists for stroke and encephalopathy, yet specific large neuropathy trials are absent from English-language records.\n\n## What scientists say\n\nResearchers describe ARA290 as reprogramming a damaging inflammatory environment into one that supports repair via the innate repair receptor. They note measurable symptom gains and early structural hints in cornea but call for larger trials. C-peptide investigators observed selective sensory improvement without broad electrophysiologic change and concluded further study is warranted. Animal researchers on BPC-157 highlight consistent nerve healing across trauma models yet stress the gap to human application.\n\n## What people say on Reddit\n\nUsers in neuropathy and small fiber neuropathy forums discuss ARA290 most often. Several report symptom relief within hours to days at doses around 4 mg daily for weeks. Some note reduced allodynia and burning. Others describe pins-and-needles flares that led them to stop. Cost and sourcing concerns appear repeatedly. A few mention combining with other approaches. BPC-157 threads focus more on general healing claims than documented neuropathy outcomes. Experiences remain anecdotal and vary widely.\n\n## What people say on X\n\nPublic posts on X about peptides for neuropathy stay sparse compared with Reddit. Occasional mentions link ARA290 to nerve repair discussions, often referencing the same human trials. Users rarely share personal outcome details in searchable posts. Broader peptide conversations emphasize research status over personal results.\n\n## What we do not know\n\nLarge phase III trials confirming long-term nerve regrowth or durable symptom control are missing for most compounds. Optimal dosing, duration, and patient selection remain unclear. Whether benefits continue after stopping treatment is unknown. Head-to-head comparisons between peptides do not exist. Effects on different neuropathy subtypes, such as chemotherapy-induced or idiopathic, lack dedicated data. Long-term safety beyond short trial periods is unproven.\n\n## Safety and limits\n\nReported side effects in human ARA290 and C-peptide trials stayed low with no major signals. Animal BPC-157 work shows no obvious toxicity at tested levels. Human experience overall remains small in scale. These compounds sit outside routine approved use for neuropathy in most regions. Any consideration requires medical oversight and awareness that evidence grades range from small human trials to animal models only.","claims":[{"id":"c1","text":"Long-acting C-peptide improved vibration perception threshold by 25% versus placebo in a 52-week RCT of 250 type 1 diabetes patients with neuropathy, but did not improve nerve conduction velocity or clinical scores.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human outcome data separates sensory improvement from other measures.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA290 increased corneal small nerve fiber density and reduced neuropathic symptom scores in placebo-controlled trials of patients with sarcoidosis-associated small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides both symptom and structural human evidence.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"BPC-157 promoted axon regeneration and functional recovery after sciatic nerve transection in rat models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Animal data on structural nerve repair; no equivalent human neuropathy trials.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report variable symptom relief with ARA290, including reduced burning and allodynia in some cases alongside occasional flares.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26884473/","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes","quote":"After 52 weeks, ... VPT had improved by 25% after 52 weeks of C-peptide therapy ... but resulted in marked improvement of VPT compared with placebo.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"ARA290 treatment over 28 days increased corneal small nerve fiber density ... In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/","title":"Stable gastric pentadecapeptide BPC 157 can improve ...","quote":"BPC 157 ... therapeutic effects ... in spinal cord injury using a rat model. Spinal cord injury recovery was ...","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/","title":"Peptide ARA-290","quote":"Has anyone tried the peptide ARA-290. It has clinical evidence of helping to slow or stop neuropathy and allow nerves to heal.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":35742,"tokens_out":3195,"cost":0.052665,"prev_hash":"genesis","hash":"71eeee2372d6da1b779254a1527b08ebbbb1b1192915446526284dd906714090"}],"provenance":[{"ts":"2026-06-29T21:52:50.194Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Neuropathy\nSlug: what-are-peptides-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\n  \"slug\": \"what-are-peptides-neuropathy\",\n  \"title\": \"What Are Peptides for Neuropathy\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.\\n\\nRepair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.\\n\\n## How these fit together\\n\\nDifferent peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.\\n\\n## What the evidence actually shows\\n\\nHuman data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)\\n\\nARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, p","tokens_in":35742,"tokens_out":3195,"cost":0,"prev":"genesis","hash":"a95cee184303f2416add90dbb1aa27c2e92158fcce314e4175fbca361a6fe416"},{"ts":"2026-07-17T02:43:33.466Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a95cee184303f2416add90dbb1aa27c2e92158fcce314e4175fbca361a6fe416","hash":"513e243ee7eafe1cd341b360c6e5dc2c7081fd7fa3ab14001d9bbd37c57e1666"}],"energy":{"passes":2,"tokens_in":35742,"tokens_out":3195,"tokens_total":38937,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"513e243ee7eafe1cd341b360c6e5dc2c7081fd7fa3ab14001d9bbd37c57e1666"},"posted_at":"2026-06-29T21:33:58.301Z","created_at":"2026-06-29T21:33:58.301Z","updated_at":"2026-07-17T02:43:33.466Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-neuropathy","json":"https://miscsubjects.com/api/articles/what-are-peptides-neuropathy","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-neuropathy","json":"/api/articles/what-are-peptides-neuropathy","markdown":"/api/articles/what-are-peptides-neuropathy/bundle?format=markdown","skill":"/api/articles/what-are-peptides-neuropathy/skill","topology":"/api/articles/what-are-peptides-neuropathy/topology","versions":"/api/articles/what-are-peptides-neuropathy/revisions","invocations":"/api/articles/what-are-peptides-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"e91f4665c0a8f907505e02764eec04b02f23412c6040688f159ea23955fd96bb","object":{"object_type":"article-object","identity":{"id":"article:what-are-peptides-neuropathy","slug":"what-are-peptides-neuropathy","title":"What Are Peptides for Neuropathy"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/what-are-peptides-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/what-are-peptides-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: what-are-peptides-neuropathy\ndescription: Apply the What Are Peptides for Neuropathy article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# What Are Peptides for Neuropathy\n\nThis Skill is the behavioral expression of [the canonical article](/a/what-are-peptides-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/what-are-peptides-neuropathy.\n- Read claims and relationships at /api/articles/what-are-peptides-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Neuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace \n\n## Representations\n\n- Human: /a/what-are-peptides-neuropathy\n- JSON: /api/articles/what-are-peptides-neuropathy\n- Relationships: /api/articles/what-are-peptides-neuropathy/topology\n- History: /api/articles/what-are-peptides-neuropathy/revisions\n"},"json":{"route":"/api/articles/what-are-peptides-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/what-are-peptides-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","what","are","peptides","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/what-are-peptides-neuropathy/invocations?status=success","failure_events":"/api/articles/what-are-peptides-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"what-are-peptides-neuropathy","title":"What Are Peptides for Neuropathy","body":"## What's breaking down\n\nNeuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.\n\nRepair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.\n\n## How these fit together\n\nDifferent peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.\n\n## What the evidence actually shows\n\nHuman data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)\n\nARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, patients reported lower neuropathic symptom scores and better quality of life after four weeks. Corneal confocal microscopy showed increased small nerve fiber density in one trial after 28 days. Skin biopsies did not show the same regrowth. Pain relief reached about 25-40 percent in some measures. (sources from Pain Reports 2016 and related PMC articles)\n\nPreclinical work on BPC-157 used rat models of sciatic nerve transection and spinal cord injury. Treated rats showed faster functional recovery, thicker regenerating axons, and better organized nerve bundles under microscope. These studies count as animal evidence only. Human reports remain limited to one small retrospective knee pain series with no neuropathy-specific outcomes.\n\nSemax studies in rats demonstrated reduced pain sensitivity and improved learning after intraperitoneal or intranasal dosing. Russian clinical use exists for stroke and encephalopathy, yet specific large neuropathy trials are absent from English-language records.\n\n## What scientists say\n\nResearchers describe ARA290 as reprogramming a damaging inflammatory environment into one that supports repair via the innate repair receptor. They note measurable symptom gains and early structural hints in cornea but call for larger trials. C-peptide investigators observed selective sensory improvement without broad electrophysiologic change and concluded further study is warranted. Animal researchers on BPC-157 highlight consistent nerve healing across trauma models yet stress the gap to human application.\n\n## What people say on Reddit\n\nUsers in neuropathy and small fiber neuropathy forums discuss ARA290 most often. Several report symptom relief within hours to days at doses around 4 mg daily for weeks. Some note reduced allodynia and burning. Others describe pins-and-needles flares that led them to stop. Cost and sourcing concerns appear repeatedly. A few mention combining with other approaches. BPC-157 threads focus more on general healing claims than documented neuropathy outcomes. Experiences remain anecdotal and vary widely.\n\n## What people say on X\n\nPublic posts on X about peptides for neuropathy stay sparse compared with Reddit. Occasional mentions link ARA290 to nerve repair discussions, often referencing the same human trials. Users rarely share personal outcome details in searchable posts. Broader peptide conversations emphasize research status over personal results.\n\n## What we do not know\n\nLarge phase III trials confirming long-term nerve regrowth or durable symptom control are missing for most compounds. Optimal dosing, duration, and patient selection remain unclear. Whether benefits continue after stopping treatment is unknown. Head-to-head comparisons between peptides do not exist. Effects on different neuropathy subtypes, such as chemotherapy-induced or idiopathic, lack dedicated data. Long-term safety beyond short trial periods is unproven.\n\n## Safety and limits\n\nReported side effects in human ARA290 and C-peptide trials stayed low with no major signals. Animal BPC-157 work shows no obvious toxicity at tested levels. Human experience overall remains small in scale. These compounds sit outside routine approved use for neuropathy in most regions. Any consideration requires medical oversight and awareness that evidence grades range from small human trials to animal models only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Long-acting C-peptide improved vibration perception threshold by 25% versus placebo in a 52-week RCT of 250 type 1 diabetes patients with neuropathy, but did not improve nerve conduction velocity or clinical scores.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human outcome data separates sensory improvement from other measures.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA290 increased corneal small nerve fiber density and reduced neuropathic symptom scores in placebo-controlled trials of patients with sarcoidosis-associated small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides both symptom and structural human evidence.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"BPC-157 promoted axon regeneration and functional recovery after sciatic nerve transection in rat models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Animal data on structural nerve repair; no equivalent human neuropathy trials.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report variable symptom relief with ARA290, including reduced burning and allodynia in some cases alongside occasional flares.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26884473/","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes","quote":"After 52 weeks, ... VPT had improved by 25% after 52 weeks of C-peptide therapy ... but resulted in marked improvement of VPT compared with placebo.","summary":"52-week RCT details on C-peptide effects in diabetic neuropathy.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"357b6ac77132eb3b8cb769b9e775eb7176179a3d49504ee8f2e0181da059c2ef"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"ARA290 treatment over 28 days increased corneal small nerve fiber density ... In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms.","summary":"Human trial summaries on ARA290 for small fiber neuropathy.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"357b6ac77132eb3b8cb769b9e775eb7176179a3d49504ee8f2e0181da059c2ef","hash":"faae3246c0170a573a2881385e7e6b2e71eefa5bb8451b52d271a5a0361a1898"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/","title":"Stable gastric pentadecapeptide BPC 157 can improve ...","quote":"BPC 157 ... therapeutic effects ... in spinal cord injury using a rat model. Spinal cord injury recovery was ...","summary":"Rat studies on BPC-157 nerve and spinal repair.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"faae3246c0170a573a2881385e7e6b2e71eefa5bb8451b52d271a5a0361a1898","hash":"d3fe610e699cbdb1daba348b8776fa33fd6c8f6fc58532104101e79a26836df4"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/","title":"Peptide ARA-290","quote":"Has anyone tried the peptide ARA-290. It has clinical evidence of helping to slow or stop neuropathy and allow nerves to heal.","summary":"Reddit discussion thread on ARA290 user experiences.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:52:48.192Z","link_status":"ok","quote_status":"unverified","prev":"d3fe610e699cbdb1daba348b8776fa33fd6c8f6fc58532104101e79a26836df4","hash":"9aeb19dfe2f2e8c91261c01ae6e00f99ccaff8daa83ae9e95cd260a2695d3055"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T21:52:50.194Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for Neuropathy","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.\n\nRepair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.\n\n## How these fit together\n\nDifferent peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.\n\n## What the evidence actually shows\n\nHuman data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)\n\nARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, patients reported lower neuropathic symptom scores and better quality of life after four weeks. Corneal confocal microscopy showed increased small nerve fiber density in one trial after 28 days. Skin biopsies did not show the same regrowth. Pain relief reached about 25-40 percent in some measures. (sources from Pain Reports 2016 and related PMC articles)\n\nPreclinical work on BPC-157 used rat models of sciatic nerve transection and spinal cord injury. Treated rats showed faster functional recovery, thicker regenerating axons, and better organized nerve bundles under microscope. These studies count as animal evidence only. Human reports remain limited to one small retrospective knee pain series with no neuropathy-specific outcomes.\n\nSemax studies in rats demonstrated reduced pain sensitivity and improved learning after intraperitoneal or intranasal dosing. Russian clinical use exists for stroke and encephalopathy, yet specific large neuropathy trials are absent from English-language records.\n\n## What scientists say\n\nResearchers describe ARA290 as reprogramming a damaging inflammatory environment into one that supports repair via the innate repair receptor. They note measurable symptom gains and early structural hints in cornea but call for larger trials. C-peptide investigators observed selective sensory improvement without broad electrophysiologic change and concluded further study is warranted. Animal researchers on BPC-157 highlight consistent nerve healing across trauma models yet stress the gap to human application.\n\n## What people say on Reddit\n\nUsers in neuropathy and small fiber neuropathy forums discuss ARA290 most often. Several report symptom relief within hours to days at doses around 4 mg daily for weeks. Some note reduced allodynia and burning. Others describe pins-and-needles flares that led them to stop. Cost and sourcing concerns appear repeatedly. A few mention combining with other approaches. BPC-157 threads focus more on general healing claims than documented neuropathy outcomes. Experiences remain anecdotal and vary widely.\n\n## What people say on X\n\nPublic posts on X about peptides for neuropathy stay sparse compared with Reddit. Occasional mentions link ARA290 to nerve repair discussions, often referencing the same human trials. Users rarely share personal outcome details in searchable posts. Broader peptide conversations emphasize research status over personal results.\n\n## What we do not know\n\nLarge phase III trials confirming long-term nerve regrowth or durable symptom control are missing for most compounds. Optimal dosing, duration, and patient selection remain unclear. Whether benefits continue after stopping treatment is unknown. Head-to-head comparisons between peptides do not exist. Effects on different neuropathy subtypes, such as chemotherapy-induced or idiopathic, lack dedicated data. Long-term safety beyond short trial periods is unproven.\n\n## Safety and limits\n\nReported side effects in human ARA290 and C-peptide trials stayed low with no major signals. Animal BPC-157 work shows no obvious toxicity at tested levels. Human experience overall remains small in scale. These compounds sit outside routine approved use for neuropathy in most regions. Any consideration requires medical oversight and awareness that evidence grades range from small human trials to animal models only.","claims":[{"id":"c1","text":"Long-acting C-peptide improved vibration perception threshold by 25% versus placebo in a 52-week RCT of 250 type 1 diabetes patients with neuropathy, but did not improve nerve conduction velocity or clinical scores.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human outcome data separates sensory improvement from other measures.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA290 increased corneal small nerve fiber density and reduced neuropathic symptom scores in placebo-controlled trials of patients with sarcoidosis-associated small fiber neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides both symptom and structural human evidence.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"BPC-157 promoted axon regeneration and functional recovery after sciatic nerve transection in rat models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Animal data on structural nerve repair; no equivalent human neuropathy trials.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report variable symptom relief with ARA290, including reduced burning and allodynia in some cases alongside occasional flares.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:52:48.749Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26884473/","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes","quote":"After 52 weeks, ... VPT had improved by 25% after 52 weeks of C-peptide therapy ... but resulted in marked improvement of VPT compared with placebo.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"ARA290 treatment over 28 days increased corneal small nerve fiber density ... In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/","title":"Stable gastric pentadecapeptide BPC 157 can improve ...","quote":"BPC 157 ... therapeutic effects ... in spinal cord injury using a rat model. Spinal cord injury recovery was ...","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/","title":"Peptide ARA-290","quote":"Has anyone tried the peptide ARA-290. It has clinical evidence of helping to slow or stop neuropathy and allow nerves to heal.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":35742,"tokens_out":3195,"cost":0.052665,"prev_hash":"genesis","hash":"71eeee2372d6da1b779254a1527b08ebbbb1b1192915446526284dd906714090"}],"provenance":[{"ts":"2026-06-29T21:52:50.194Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Neuropathy\nSlug: what-are-peptides-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\n  \"slug\": \"what-are-peptides-neuropathy\",\n  \"title\": \"What Are Peptides for Neuropathy\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.\\n\\nRepair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.\\n\\n## How these fit together\\n\\nDifferent peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.\\n\\n## What the evidence actually shows\\n\\nHuman data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)\\n\\nARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, p","tokens_in":35742,"tokens_out":3195,"cost":0,"prev":"genesis","hash":"a95cee184303f2416add90dbb1aa27c2e92158fcce314e4175fbca361a6fe416"},{"ts":"2026-07-17T02:43:33.466Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a95cee184303f2416add90dbb1aa27c2e92158fcce314e4175fbca361a6fe416","hash":"513e243ee7eafe1cd341b360c6e5dc2c7081fd7fa3ab14001d9bbd37c57e1666"}],"energy":{"passes":2,"tokens_in":35742,"tokens_out":3195,"tokens_total":38937,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"513e243ee7eafe1cd341b360c6e5dc2c7081fd7fa3ab14001d9bbd37c57e1666"},"posted_at":"2026-06-29T21:33:58.301Z","created_at":"2026-06-29T21:33:58.301Z","updated_at":"2026-07-17T02:43:33.466Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-neuropathy","json":"https://miscsubjects.com/api/articles/what-are-peptides-neuropathy","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-neuropathy","json":"/api/articles/what-are-peptides-neuropathy","markdown":"/api/articles/what-are-peptides-neuropathy/bundle?format=markdown","skill":"/api/articles/what-are-peptides-neuropathy/skill","topology":"/api/articles/what-are-peptides-neuropathy/topology","versions":"/api/articles/what-are-peptides-neuropathy/revisions","invocations":"/api/articles/what-are-peptides-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"e91f4665c0a8f907505e02764eec04b02f23412c6040688f159ea23955fd96bb"}}}